Rate of and reasons for discontinuation in study INCB18424-251
| . | MDACC . | Mayo Clinic Rochester . |
|---|---|---|
| Patients enrolled, N | 107 | 51 |
| Patients remaining on study, n (%) | 58 (54) | 5 (10) |
| Patients who discontinued, n (%) | 49 (46) | 46 (90) |
| Discontinued by 1 y, % | 24 | 51† |
| Discontinued by 2 y, % | 36 | 72† |
| Discontinued by 3 y, % | 46‡ | 89† |
| Primary reason for discontinuation,*n (%) | ||
| Death | 13 (12.1) | 4 (7.8) |
| Progressive disease | 12 (11.2) | 10 (19.6) |
| Patient withdrawal of consent | 7 (6.5) | 15 (29.4) |
| Physician decision to discontinue | 5 (4.7) | 12 (23.5) |
| Intercurrent illness | 3 (2.8) | 0 |
| Unacceptable toxicity | 3 (2.8) | 1 (2.0) |
| Other | 6 (5.6) | 4 (7.8) |
| . | MDACC . | Mayo Clinic Rochester . |
|---|---|---|
| Patients enrolled, N | 107 | 51 |
| Patients remaining on study, n (%) | 58 (54) | 5 (10) |
| Patients who discontinued, n (%) | 49 (46) | 46 (90) |
| Discontinued by 1 y, % | 24 | 51† |
| Discontinued by 2 y, % | 36 | 72† |
| Discontinued by 3 y, % | 46‡ | 89† |
| Primary reason for discontinuation,*n (%) | ||
| Death | 13 (12.1) | 4 (7.8) |
| Progressive disease | 12 (11.2) | 10 (19.6) |
| Patient withdrawal of consent | 7 (6.5) | 15 (29.4) |
| Physician decision to discontinue | 5 (4.7) | 12 (23.5) |
| Intercurrent illness | 3 (2.8) | 0 |
| Unacceptable toxicity | 3 (2.8) | 1 (2.0) |
| Other | 6 (5.6) | 4 (7.8) |
Data provided by Incyte Corporation upon MDACC request.
As categorized by defined headings on case report forms filled out by the investigator.
Discontinuation rates as published in Tefferi et al in 2011.18
Note: not all ongoing patients have reached year 3; by Kaplan-Meier analysis, the discontinuation rate at year 3 was 53%.